DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,115 filers reported holding DANAHER CORPORATION in Q3 2017. The put-call ratio across all filers is 0.49 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $403,000 | -55.8% | 4,348 | -59.1% | 0.09% | -60.4% |
Q3 2017 | $911,000 | -51.4% | 10,622 | -52.2% | 0.22% | -53.4% |
Q2 2017 | $1,874,000 | -24.0% | 22,207 | -29.9% | 0.48% | -28.6% |
Q4 2016 | $2,466,000 | -2.8% | 31,684 | -2.2% | 0.67% | -4.7% |
Q3 2016 | $2,538,000 | -25.4% | 32,386 | -3.8% | 0.70% | -27.4% |
Q2 2016 | $3,400,000 | -39.9% | 33,666 | -45.9% | 0.96% | +24.9% |
Q1 2016 | $5,659,000 | +78.9% | 62,261 | +82.7% | 0.77% | -21.1% |
Q4 2015 | $3,164,000 | +7.2% | 34,073 | -1.7% | 0.98% | +2.7% |
Q3 2015 | $2,952,000 | -0.5% | 34,648 | -0.1% | 0.95% | +3.6% |
Q2 2015 | $2,968,000 | +0.1% | 34,688 | -0.6% | 0.92% | -0.9% |
Q1 2015 | $2,964,000 | -1.5% | 34,913 | -0.6% | 0.93% | -7.2% |
Q4 2014 | $3,009,000 | +11.6% | 35,118 | -1.0% | 1.00% | +3.3% |
Q3 2014 | $2,696,000 | -5.6% | 35,488 | -2.2% | 0.97% | -6.8% |
Q2 2014 | $2,855,000 | +4.3% | 36,268 | -0.6% | 1.04% | +1.7% |
Q1 2014 | $2,736,000 | -3.2% | 36,483 | -0.3% | 1.02% | -5.2% |
Q4 2013 | $2,826,000 | +8.2% | 36,608 | -2.9% | 1.08% | -2.4% |
Q3 2013 | $2,613,000 | +9.0% | 37,698 | -0.5% | 1.10% | +0.8% |
Q2 2013 | $2,397,000 | – | 37,873 | – | 1.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |